10-Q: Harrow Inc. Reports Increased Revenue Driven by Branded Ophthalmology Products in Q1 2025

Harrow Inc. saw a revenue increase in Q1 2025, driven by strong sales of branded ophthalmology products, while navigating debt refinancing and regulatory considerations.

Summary

• Harrow Inc. reported its financial results for the quarter ended March 31, 2025.
• The company's total revenues increased to $47.83 million, compared to $34.59 million in the same period last year.
• This growth was primarily driven by increased sales of branded ophthalmology products, which rose to $27.78 million from $13.87 million.
• ImprimisRx revenue decreased slightly to $20.05 million from $20.72 million.
• The company reported a net loss of $17.78 million, or $0.50 per share, compared to a net loss of $13.57 million, or $0.38 per share, in the prior year.
• The company is in discussions to refinance its Oaktree Loan and 2026 Notes, which mature in January and April 2026, respectively.
• Management believes it is probable that the company will be able to refinance the Oaktree Loan and the 2026 Notes based on the company's collateral strength and expected cash flows from operations.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth is positive, the increased net loss and the need to refinance debt obligations introduce uncertainty. The company's strategic initiatives and market position provide some optimism.

Positives

• Total revenues increased significantly, driven by branded product sales.
• The company is actively working to refinance its debt obligations.
• The company has a patient access program called VEVYE Access for All to increase patient access to VEVYE at an out-of-pocket cost of $59 or below.
• The company initiated Project Beagle to transition ImprimisRx customers from compounded formulations to FDA-approved products.

Negatives

• The company's net loss increased compared to the same period last year.
• The company faces the need to refinance its Oaktree Loan and 2026 Notes, which mature in January and April 2026, respectively.
• ImprimisRx revenue decreased slightly compared to the same period last year.

Risks

• The company's ability to refinance its debt obligations is not guaranteed.
• Regulatory standards, approvals, guidelines and inspections could impact the company's ability to make, dispense, and sell certain products.
• The company's reliance on a few key suppliers and customers could pose a risk.
• The company's success depends on its ability to successfully implement its business plan, develop and commercialize its products, product candidates and proprietary formulations in a timely manner or at all.

Future Outlook

The company expects to refinance its Oaktree Loan and 2026 Notes during 2025 and believes it is probable that it will be able to do so based on its collateral strength and expected cash flows from operations.

Industry Context

Harrow operates in the competitive eyecare pharmaceutical market, facing competition from both branded and generic pharmaceutical companies, as well as compounding pharmacies. The company's focus on innovative ophthalmic products and its ImprimisRx compounding business positions it to address specific patient needs and market segments.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without specific competitor data.
• However, the growth in branded product revenue suggests Harrow is gaining market share in its targeted segments.
• The company's gross margins are within a reasonable range for specialty pharmaceutical companies, but the decrease in margins warrants monitoring.
• Comparisons to companies like Alcon, Bausch + Lomb, or Novartis (ophthalmology divisions) would require a deeper analysis of product portfolios and market strategies.

Legal Proceedings

• The company is involved in various legal proceedings, including the Ocular Science, Inc. et. al lawsuit, where ImprimisRx, LLC received a $34.9 million jury verdict award.

Stakeholder Impact

• Shareholders: The increased revenue is a positive sign, but the increased net loss and debt refinancing needs may concern investors.
• Employees: The company's growth initiatives and product development efforts may create opportunities for employees.
• Customers: The VEVYE Access for All program aims to improve patient access to medication.
• Creditors: The company's ability to refinance its debt obligations is crucial for creditors.

Next Steps

• The company will continue to focus on growing its branded product sales.
• The company will continue to pursue refinancing options for its Oaktree Loan and 2026 Notes.
• The company will continue to implement Project Beagle to transition ImprimisRx customers to FDA-approved products.

Key Dates

Keywords

Harrow, ophthalmology, pharmaceuticals, revenue, net loss, refinancing, branded products, ImprimisRx, VEVYE, IHEEZO, Oaktree Loan, 2026 Notes